Trimethoprim-metformin interaction and its genetic modulation by OCT2 and MATE1 transporters

British Journal of Clinical Pharmacology

Volumn 76, Issue 5, 2013, Pages 787-796

  Grün, Barbara ^a,c   Kiessling, Michael K ^a   Burhenne, Jürgen ^a   Riedel, Klaus Dieter ^a   Weiss, Johanna ^a   Rauch, Geraldine ^b   Haefeli, Walter E ^a   Czock, David ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Drug interaction; Genetic polymorphism; Metformin; Pharmacokinetics; Trimethoprim

Indexed keywords

BIOLOGICAL MARKER; C PEPTIDE; CREATININE; GLUCOSE; INSULIN; LACTIC ACID; MEMBRANE PROTEIN; METFORMIN; MULTIDRUG AND TOXIN EXTRUSION 1; ORGANIC CATION TRANSPORTER 2; TRIMETHOPRIM; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD SAMPLING; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIARRHEA; DRUG CLEARANCE; DRUG EFFECT; DRUG HALF LIFE; DRUG INHIBITION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL PAIN; GENETIC POLYMORPHISM; HUMAN; HUMAN EXPERIMENT; KIDNEY FUNCTION; LACTATE BLOOD LEVEL; LOSS OF APPETITE; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SIDE EFFECT; VOMITING; WEAKNESS;

DRUG INTERACTION; GENETIC POLYMORPHISM; METFORMIN; PHARMACOKINETICS; TRIMETHOPRIM;

ADULT; ANTI-INFECTIVE AGENTS, URINARY; AREA UNDER CURVE; CREATININE; DRUG INTERACTIONS; HALF-LIFE; HUMANS; HYPOGLYCEMIC AGENTS; LACTIC ACID; MALE; METFORMIN; MIDDLE AGED; MOLECULAR SEQUENCE DATA; ORGANIC CATION TRANSPORT PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; TRIMETHOPRIM; YOUNG ADULT;

EID: 84885148050     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12079     Document Type: Article

References (46)

1. Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong JK, Furlong TJ, Greenfield JR, Greenup LC, Kirkpatrick CM, Ray JE, Timmins P, Williams KM. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 2011; 50: 81-98.
2. Chen L, Pawlikowski B, Schlessinger A, More SS, Stryke D, Johns SJ, Portman MA, Chen E, Ferrin TE, Sali A, Giacomini KM. Role of organic cation transporter 3 (SLC22A3) and its missense variants in the pharmacologic action of metformin. Pharmacogenet Genomics 2010; 20: 687-699.
3. Tzvetkov MV, Vormfelde SV, Balen D, Meineke I, Schmidt T, Sehrt D, Sabolić I, Koepsell H, Brockmöller J. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin Pharmacol Ther 2009; 86: 299-306.
4. Koepsell H, Lips K, Volk C. Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res 2007; 24: 1227-1251.
5. Zhou M, Xia L, Wang J. Metformin transport by a newly cloned proton-stimulated organic cation transporter (plasma membrane monoamine transporter) expressed in human intestine. Drug Metab Dispos 2007; 35: 1956-1962.
6. Xia L, Engel K, Zhou M, Wang J. Membrane localization and pH-dependent transport of a newly cloned organic cation transporter (PMAT) in kidney cells. Am J Physiol Renal Physiol 2007; 292: F682-690.
7. Masuda S, Terada T, Yonezawa A, Tanihara Y, Kishimoto K, Katsura T, Ogawa O, Inui K. Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J Am Soc Nephrol 2006; 17: 2127-2135.
8. Müller J, Lips KS, Metzner L, Neubert RH, Koepsell H, Brandsch M. Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). Biochem Pharmacol 2005; 70: 1851-1860.
9. Otsuka M, Matsumoto T, Morimoto R, Arioka S, Omote H, Moriyama Y. A human transporter protein that mediates the final excretion step for toxic organic cations. Proc Natl Acad Sci U S A 2005; 102: 17923-17928.
10. Proctor WR, Bourdet DL, Thakker DR. Mechanisms underlying saturable intestinal absorption of metformin. Drug Metab Dispos 2008; 36: 1650-1658.
11. Meyer zu Schwabedissen HE, Verstuyft C, Kroemer HK, Becquemont L, Kim RB. Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. Am J Physiol Renal Physiol 2010; 298: F997-F1005.
12. Ito S, Kusuhara H, Kuroiwa Y, Wu C, Moriyama Y, Inoue K, Kondo T, Yuasa H, Nakayama H, Horita S, Sugiyama Y. Potent and specific inhibition of mMate1-mediated efflux of type I organic cations in the liver and kidney by pyrimethamine. J Pharmacol Exp Ther 2010; 333: 341-350.
13. Tsuda M, Terada T, Ueba M, Sato T, Masuda S, Katsura T, Inui K. Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells. J Pharmacol Exp Ther 2009; 329: 185-191.
14. Zolk O, Solbach TF, König J, Fromm MF. Functional characterization of the human organic cation transporter 2 variant p.270Ala>Ser. Drug Metab Dispos 2009; 37: 1312-1318.
15. Glube N, Langguth P. Caki-1 cells as a model system for the interaction of renally secreted drugs with OCT3. Nephron Physiol 2008; 108: 18-28.
16. Wang ZJ, Yin OQ, Tomlinson B, Chow MS. OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. Pharmacogenet Genomics 2008; 18: 637-645.
17. Somogyi A, Stockley C, Keal J, Rolan P, Bochner F. Reduction of metformin renal tubular secretion by cimetidine in man. Br J Clin Pharmacol 1987; 23: 545-551.
18. Kusuhara H, Ito S, Kumagai Y, Jiang M, Shiroshita T, Moriyama Y, Inoue K, Yuasa H, Sugiyama Y. Effects of a MATE protein inhibitor, pyrimethamine, on the renal elimination of metformin at oral microdose and at therapeutic dose in healthy subjects. Clin Pharmacol Ther 2011; 89: 837-844.
19. Dawson D, Conlon C. Case study: metformin-associated lactic acidosis: could orlistat be relevant? Diabetes Care 2003; 26: 2471-2472.
20. Shah VP, Midha KK, Findlay JW, Hill HM, Hulse JD, McGilveray IJ, McKay G, Miller KJ, Patnaik RN, Powell ML, Tonelli A, Viswanathan CT, Yacobi A. Bioanalytical method validation - a revisit with a decade of progress. Pharm Res 2000; 17: 1551-1557.
21. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
22. Sambol NC, Chiang J, O'Conner M, Liu CY, Lin ET, Goodman AM, Benet LZ, Karam JH. Pharmacokinetics and pharmacodynamics of metformin in healthy subjects and patients with noninsulin-dependent diabetes mellitus. J Clin Pharmacol 1996; 36: 1012-1021.
23. Sambol NC, Chiang J, Lin ET, Goodman AM, Liu CY, Benet LZ, Cogan MG. Kidney function and age are both predictors of pharmacokinetics of metformin. J Clin Pharmacol 1995; 35: 1094-1102.
24. Protti A, Russo R, Tagliabue P, Vecchio S, Singer M, Rudiger A, Foti G, Rossi A, Mistraletti G, Gattinoni L. Oxygen consumption is depressed in patients with lactic acidosis due to biguanide intoxication. Crit Care 2010; 14: R22.
25. Dykens JA, Jamieson J, Marroquin L, Nadanaciva S, Billis PA, Will Y. Biguanide-induced mitochondrial dysfunction yields increased lactate production and cytotoxicity of aerobically-poised HepG2 cells and human hepatocytes in vitro. Toxicol Appl Pharmacol 2008; 233: 203-210.
26. Wills BK, Bryant SM, Buckley P, Seo B. Can acute overdose of metformin lead to lactic acidosis? Am J Emerg Med 2010; 28: 857-861.
27. Seidowsky A, Nseir S, Houdret N, Fourrier F. Metformin-associated lactic acidosis: a prognostic and therapeutic study. Crit Care Med 2009; 37: 2191-2196.
28. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010; (4): CD002967.
29. van Berlo-van de Laar IR, Vermeij CG, Doorenbos CJ. Metformin associated lactic acidosis: incidence and clinical correlation with metformin serum concentration measurements. J Clin Pharm Ther 2011; 36: 376-382.
30. Ixkes MC, Koopman MG, van Acker BA, Weber JA, Arisz L. Cimetidine improves GFR-estimation by the Cockcroft and Gault formula. Clin Nephrol 1997; 47: 229-236.
31. van Acker BA, Koomen GC, Koopman MG, de Waart DR, Arisz L. Creatinine clearance during cimetidine administration for measurement of glomerular filtration rate. Lancet 1992; 340: 1326-1329.
32. Hilbrands LB, Artz MA, Wetzels JF, Koene RA. Cimetidine improves the reliability of creatinine as a marker of glomerular filtration. Kidney Int 1991; 40: 1171-1176.
33. Urakami Y, Kimura N, Okuda M, Inui K. Creatinine transport by basolateral organic cation transporter hOCT2 in the human kidney. Pharm Res 2004; 21: 976-981.
34. Kastrup J, Petersen P, Bartram R, Hansen JM. The effect of trimethoprim on serum creatinine. Br J Urol 1985; 57: 265-268.
35. Kainer G, Rosenberg AR. Effect of co-trimoxazole on the glomerular filtration rate of healthy adults. Chemotherapy 1981; 27: 229-232.
36. Berglund F, Killander J, Pompeius R. Effect of trimethoprim-sulfamethoxazole on the renal excretion of creatinine in man. J Urol 1975; 114: 802-808.
37. Kalowski S, Nanra RS, Mathew TH, Kincaid-Smith P. Deterioration in renal function in association with co-trimoxazole therapy. Lancet 1973; 1: 394-397.
38. Hoppu K. Age differences in trimethoprim pharmacokinetics: need for revised dosing in children? Clin Pharmacol Ther 1987; 41: 336-343.
39. Schentag JJ, Cerra FB, Calleri GM, Leising ME, French MA, Bernhard H. Age, disease, and cimetidine disposition in healthy subjects and chronically ill patients. Clin Pharmacol Ther 1981; 29: 737-743.
40. Almond DS, Szwandt IS, Edwards G, Lee MG, Winstanley PA. Disposition of intravenous pyrimethamine in healthy volunteers. Antimicrob Agents Chemother 2000; 44: 1691-1693.
41. Obach RS, Lombardo F, Waters NJ. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metab Dispos 2008; 36: 1385-1405.
42. Rowland M, Matin SB. Kinetics of drug-drug interactions. J Pharmacokinet Biopharm 1973; 1: 553-567.
43. Zamek-Gliszczynski MJ, Kalvass JC, Pollack GM, Brouwer KL. Relationship between drug/metabolite exposure and impairment of excretory transport function. Drug Metab Dispos 2009; 37: 386-390.
44. Müller F, König J, Glaeser H, Schmidt I, Zolk O, Fromm MF, Maas R. Molecular mechanism of renal tubular secretion of the antimalarial drug chloroquine. Antimicrob Agents Chemother 2011; 55: 3091-3098.
45. Tsuda M, Terada T, Mizuno T, Katsura T, Shimakura J, Inui K. Targeted disruption of the multidrug and toxin extrusion 1 (mate1) gene in mice reduces renal secretion of metformin. Mol Pharmacol 2009; 75: 1280-1286.
46. Toyama K, Yonezawa A, Masuda S, Osawa R, Hosokawa M, Fujimoto S, Inagaki N, Inui K, Katsura T. Loss of multidrug and toxin extrusion 1 (MATE1) is associated with metformin-induced lactic acidosis. Br J Pharmacol 2012; 166: 1183-1191.